|Mr. Said Samih Taleb Darwazah||Exec. Chairman||N/A||N/A||60|
|Mr. Mazen Samih Taleb Darwazeh||Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets||N/A||N/A||59|
|Mr. Sigurdur Oli Olafsson||CEO & Exec. Director||N/A||N/A||48|
|Mr. Khalid Walid Hussni Nabilsi||Chief Financial Officer||N/A||N/A||45|
|Dr. Surendera Tyagi||Group Chief Scientific Officer and Global Head of R&D||N/A||N/A||N/A|
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas. This segment's principal products include Amoclan, Blopress, Omnicef, Prograf, and Suprax. The Injectables segment markets 201 products in 571 dosage strengths and forms for anti-infective, cardiovascular, diabetes, controlled substances, gastro-intestinal, oncology, CNS, respiratory, and miscellaneous therapeutic areas. This segment also offers sterile liquid, powder, lyophilized, and cytotoxic products. This segment's principal products include fentanyl, glycopyrrolate, neostigmine, nicardipine, and thiotepa. The Generics segment provides 109 products in 375 dosage strengths and forms for therapeutic areas, including anti-infective, controlled substances, oncology, and miscellaneous therapeutic areas. This segment's principal products include amoxicillin, buprenorphine, butalbital, acetaminophen and caffeine, colchicine, and fluticasone. This segment markets its products to chain stores, wholesalers, distributors, health systems, and governmental agencies in the form of tablets, capsules, solutions, and suspensions. In addition, the company manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. Hikma Pharmaceuticals PLC was founded in 1978 and is based in London, the United Kingdom.
Hikma Pharmaceuticals PLC’s ISS Governance QualityScore as of February 1, 2018 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 1; Compensation: 9.